Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 02:15:49 GMT 2025
by
admin
on
Wed Apr 02 02:15:49 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
2PDN1S3FVX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2PDN1S3FVX
Created by
admin on Wed Apr 02 02:15:49 GMT 2025 , Edited by admin on Wed Apr 02 02:15:49 GMT 2025
|
PRIMARY | |||
|
Q07869
Created by
admin on Wed Apr 02 02:15:49 GMT 2025 , Edited by admin on Wed Apr 02 02:15:49 GMT 2025
|
PRIMARY |
| Linkage Type | Residue Index | |||
|---|---|---|---|---|
| COORDINATION COMPOUND | 1_139 | 1_143 | 1_153 | 1_156 |
| COORDINATION COMPOUND | 1_102 | 1_105 | 1_119 | 1_122 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVATOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
|
ACTIVATOR -> TARGET | |||
|
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
WEAK AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
WEAK AGONIST->TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
SELECTIVE
|
||
|
AGONIST -> TARGET | |||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Tesaglitazar is a novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonist.
|
||
|
|
AGONIST -> TARGET |
EC50
|
||
|
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
sarogli tazar has a predominant affinity for the PPAR-.ALPHA. isoform, and an intermediate affinity for PPAR-.GAMMA.
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
EC50
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
AGONIST
EC50
|
||
|
INHIBITOR -> TARGET |
PPAR? antagonist leading to the inhibition of fatty acid oxidation which is critical for the survival of tumor cells
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
The PPAR? potency and selectivity of 3 were further confirmed by testing it in cotransfection assays in HepG2 cells using full length human PPAR? and PPAR? receptors..
EC50
|
![Structure of 5-[(2,4-Dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide](/img/462880ff-b0e2-4a28-ac0c-e4d01fd242df.svg "Structure of 5-[(2,4-Dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide")
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO_ACID_SUBSTITUTION | [1_102] [1_105] [1_119] [1_122] | SITE_SPECIFIC | C4-TYPE ZINC FINGER | C56TF4V7OP | ||
| AMINO_ACID_SUBSTITUTION | [1_139] [1_143] [1_153] [1_156] | SITE_SPECIFIC | C4-TYPE ZINC FINGER | C56TF4V7OP |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|